Rhythm Biosciences Limited

ASX:RHY Stock Report

Market Cap: AU$16.7m

Rhythm Biosciences Past Earnings Performance

Past criteria checks 0/6

Rhythm Biosciences's earnings have been declining at an average annual rate of -26%, while the Healthcare industry saw earnings growing at 1.5% annually. Revenues have been growing at an average rate of 34.8% per year.

Key information

-26.0%

Earnings growth rate

-8.5%

EPS growth rate

Healthcare Industry Growth2.4%
Revenue growth rate34.8%
Return on equity-694.3%
Net Margin-417.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Aug 09
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Apr 11
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Revenue & Expenses Breakdown

How Rhythm Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:RHY Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232-954
30 Sep 233-864
30 Jun 233-884
31 Mar 233-874
31 Dec 223-865
30 Sep 223-965
30 Jun 222-965
31 Mar 222-965
31 Dec 212-955
30 Sep 212-845
30 Jun 211-735
31 Mar 211-533
31 Dec 201-432
30 Sep 201-422
30 Jun 200-422
31 Mar 200-421
31 Dec 191-321
30 Sep 191-321
30 Jun 191-331
31 Mar 191-321
31 Dec 180-321
30 Sep 180-221
30 Jun 180-210

Quality Earnings: RHY is currently unprofitable.

Growing Profit Margin: RHY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RHY is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.

Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-19.1%).


Return on Equity

High ROE: RHY has a negative Return on Equity (-694.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.